Guangshengtang: New crown oral drug GST-HG171 received clinical trial approval notice
Read Time:17 Second
On September 25, KWS announced that its holding subsidiary, KWS Zhonglin, received the Notice of Drug Clinical Trial Approval from the State Drug Administration for GST-HG171, a class I innovative drug for oral small molecule broad-spectrum anti-novel coronavirus 3CL protease inhibitor, achieving a key milestone in the innovative development of new coronary drugs.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating